Sarepta Therapeutics: When Bears Become Bulls

Sarepta Therapeutics ( SRPT ) got what it needed when the FDA granted it accelerated approval for its Duchenne Muscular Dystrophy treatment , and now at least one analyst who'd been fairly bearish on the stock-- Janney's Debjit Chattopadhyay --has upgraded his rating to Buy. He explains why: